LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team

Access Course

Are you familiar with how to incorporate lymphocyte-activation gene 3 (LAG-3) inhibition into the management of metastatic melanoma? Find out more here!

Available beginning: November 16th, 2023

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the LAG-3 inhibitor-containing regimens used for the treatment of metastatic melanoma
  • Have greater competence related to determining patient eligibility for LAG-3 inhibitor-containing regimens in metastatic melanoma and creating personalized care plans for patients with metastatic melanoma as part of the MDT
  • Demonstrate greater confidence in their ability to engage patients with metastatic melanoma in shared decision-making for treatment considerations
Accreditation Council for Continuing Medical Education and ABIM Maintenance of Certification
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 1.00